14 completed. 14 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 14 | Completed 14 |
Follow Heavy Menstrual Bleeding: new trials by email Literature Review of Heavy Menstrual Bleeding trials Research Report on Heavy Menstrual Bleeding
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Treatment of Heavy and/or Prolonged Menstrual Bleeding Without Organic Cause combined contraceptive pills (microcept), medroxyprogesterone acetate (progest), mefenamic acid (ponstan forte) - Improve Quality of Life, Heavy Menstrual Bleeding | Phase 3 | Completed | Assiut University | 240 | 2017-11-01 | 2021-06-04 |
| LIBERTY EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids Relugolix, Estradiol/norethindrone acetate - Heavy Menstrual Bleeding, Uterine Fibroid | Phase 3 | Completed | Myovant Sciences GmbH | 477 | 2017-10-19 | 2024-05-09 |
| Long-Term Safety Study of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women Elagolix, Estradiol /norethindrone acetate (E2/NETA), E2/NETA Placebo - Heavy Menstrual Bleeding, Uterine Fibroids | Phase 3 | Completed | AbbVie | 478 | 2017-09-13 | 2025-07-22 |
| LIBERTY 2: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids Relugolix, Estradiol/norethindrone acetate, Relugolix placebo - Heavy Menstrual Bleeding, Uterine Fibroid | Phase 3 | Completed | Myovant Sciences GmbH | 382 | 2017-06-14 | 2022-04-20 |
| Efficacy and Safety of OBE2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids OBE2109, Placebo to match OBE2109, Placebo to match Add-back - Uterine Fibroids, Heavy Menstrual Bleeding | Phase 3 | Completed | ObsEva SA | 511 | 2017-05-23 | 2021-03-05 |
| LIBERTY 1: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids Relugolix, Estradiol/norethindrone acetate, Estradiol/norethindrone acetate placebo - Heavy Menstrual Bleeding, Uterine Fibroid | Phase 3 | Completed | Myovant Sciences GmbH | 388 | 2017-04-26 | 2022-04-19 |
| Efficacy and Safety of OBE2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids OBE2109, Placebo to match OBE2109, Placebo to match Add-back - Uterine Fibroids, Heavy Menstrual Bleeding | Phase 3 | Completed | ObsEva SA | 526 | 2017-04-20 | 2021-06-09 |
| An Extension Study to Evaluate the Efficacy and Safety of Elagolix in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids Estradiol/Norethindrone Acetate, Elagolix - Uterine Fibroids, Heavy Menstrual Bleeding | Phase 3 | Completed | AbbVie | 433 | 2016-09-14 | 2021-07-13 |
| Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women (Replicate Study) Elagolix, Placebo for Estradiol/Norethindrone Acetate, Estradiol/Norethindrone Acetate - Uterine Fibroids, Heavy Menstrual Bleeding | Phase 3 | Completed | AbbVie | 378 | 2016-02-03 | 2021-07-13 |
| Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women Elagolix, Placebo for Estradiol/Norethindrone Acetate, Estradiol/Norethindrone Acetate - Uterine Fibroids, Heavy Menstrual Bleeding | Phase 3 | Completed | AbbVie | 413 | 2015-12-22 | 2020-06-29 |
| Therapeutic Equivalence Trial of Two Hormonal-IUDs in Patients With Heavy Menstrual Bleeding Levosert-20, Mirena - Heavy Menstrual Bleeding | Phase 3 | Completed | Uteron Pharma S.A. | 280 | 2007-12-01 | 2012-09-28 |
| Efficacy and Safety of XP12B in Women With Menorrhagia Tranexamic acid tablets, Placebo tablets - Menorrhagia, Heavy Menstrual Bleeding | Phase 3 | Completed | Ferring Pharmaceuticals | 304 | 2006-11-01 | 2015-05-13 |
| Efficacy and Safety Study of XP12B in Women With Menorrhagia Tranexamic acid tablets, Placebo tablets - Menorrhagia, Heavy Menstrual Bleeding | Phase 3 | Completed | Ferring Pharmaceuticals | 196 | 2006-10-01 | 2011-05-04 |
| Safety Study of XP12B in Women With Menorrhagia Tranexamic acid tablets (XP12B) - Menorrhagia, Heavy Menstrual Bleeding | Phase 3 | Completed | Ferring Pharmaceuticals | 784 | 2005-06-01 | 2010-06-15 |
Menorrhagia (14) · Leiomyoma (9)
Female Urogenital Diseases (14) · Female Urogenital Diseases and Pregnancy Complications (14) · Genital Diseases (14) · Genital Diseases, Female (14) · Hemorrhage (14) · Menstruation Disturbances (14) · Pathologic Processes (14) · Pathological Conditions, Signs and Symptoms (14) · Urogenital Diseases (14) · Uterine Diseases (14) · Uterine Hemorrhage (14) · Neoplasms (9) · Neoplasms by Histologic Type (9) · Neoplasms, Connective and Soft Tissue (9) · Neoplasms, Muscle Tissue (9)
estradiol, norethindrone drug combination (6) · Estradiol (5) · elagolix (4) · Norethindrone Acetate (3) · Tranexamic Acid (3) · relugolix (3) · linzagolix (2) · Levonorgestrel (1) · Medroxyprogesterone Acetate (1) · Mefenamic Acid (1) · Progest (1)
AbbVie (4) · Ferring Pharmaceuticals (3) · Myovant Sciences GmbH (3) · ObsEva SA (2) · Assiut University (1) · Uteron Pharma S.A. (1)
United States (12) · Poland (4) · Brazil (3) · Canada (3) · Czechia (3) · Hungary (3) · Puerto Rico (3) · South Africa (3) · Belgium (2) · Chile (2) · Italy (2) · Bulgaria (1) · Egypt (1) · Latvia (1) · Lithuania (1)
ObsEva SA (2)
PMID 34878624, PMID 36357960, PMID 37477173, PMID 37863160, PMID 21043553, PMID 31971678, PMID 33596357, PMID 33650259, PMID 34553161, PMID 34582715, PMID 35415708, PMID 35675604, PMID 36116480, PMID 37183454, PMID 39381651, PMID 39466126, PMID 40326221, PMID 40543832, PMID 20859150, PMID 20942615, PMID 21777897, PMID 21867401, PMID 32702363, PMID 40320117
2016 (2), 2017 (1)